Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 23, 2011. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 330,000 Ordinary shares of 25 pence each.
- Purchase Date: February 23, 2011.
- Price Range: Highest price paid was 1,180.0 pence per share; lowest price paid was 1,168.0 pence per share.
- Treasury Holdings (Settled): 483,179,284 shares (8.52% of total issued share capital).
- Treasury Holdings (Including Unsettled): 484,034,284 shares (9.33% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,187,676,169 shares.
Material Changes
The filing reports a reduction in outstanding shares due to the purchase of 330,000 shares. These shares are intended to be held in Treasury. The filing does not provide comparative data against a prior period for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The primary purpose is to disclose the share buyback and update the share count for regulatory transparency under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (483,179,284 settled vs. 484,034,284 including unsettled).
- Confirm the percentage of total voting rights represented by Treasury shares (9.33%).
- Check the total number of shares in issue excluding Treasury (5,187,676,169) for denominator calculations regarding disclosure thresholds.
- Review the price range paid (1,168.0 to 1,180.0 pence) against market prices on February 23, 2011.